In order to remove the free form of PGE1 ester and collect the solid microspheres, the microspheres were washed repeatedly by centrifugation with distilled water containing 0.2% tween 80. the washed microsphere precipitation was lyophilized to remove the residual organic solvent and water and then the dried solid PGE1 ester microspheres were recovered.
Measurement of Microsphere Particle Size
PGE1-loaded-PLGA microspheres were suspended in distilled water and dispersed by sonication for 1 min. The particle size was measured using a laser diffraction particle size analyzer (SALD-2100, Shimadzu, Kyoto, Japan).
Morphologic Studies by Scanning Electron Microscopy
After lyophilization, the microspheres were mounted on an aluminum stub and coated with a thin layer (200 A°) of gold by ion sputter (model E-1010; Hitachi, Tokyo, Japan). The morphology of the PGE1-loaded-PLGA microspheres was visualized with a scanning electron microscope (model S-2460N; Hitachi).
In Vitro Release Profile of PGE1 From PLGA Microspheres
PGE1-loaded-PLGA microspheres were suspended in phosphate-buffered saline (PBS) containing 0.2% tween 80 to adjust the concentration of PGE1 to 100 μg/ml and completely dispersed by mixing with a vortex and sonicator. The solution was divided into 1 ml samples and incubated at 37°C. At various time intervals, the aliquots were centrifuged for 5 min at 12,000 rpm (n=3 for each). The supernatant was discarded and the pellet was dissolved with phydroxy benzoic acid n-nonyl ester in acetonitrile. The concentration of PGE1 in the solution was analyzed by high performance liquid chromatography (HPLC).
In Vivo Release Profile of PGE1 From PLGA Microspheres PGE1-loaded-PLGA microspheres were suspended in PBS containing 0.2% tween 80 to adjust the concentration of PGE1 to 500 μg/ml and completely dispersed by mixing with a vortex and sonicator. PGE1-100 μg/kg-loaded-PLGA was injected into the thigh muscle of C57BL/6 mice under ether anesthesia.
At 14 days and 28 days after injection, mice were euthanazed with an overdose of pentobarbital (n=6 for each). The thigh muscles were resected and homogenized in 15 ml of dichloromethane. The homogenates were centrifuged at 3,000 rpm for 5 min; 750 μl of the lower phase was transferred into a glass test tube and 10 μl of p-hydroxy benzoic acid n-nonyl ester in acetonitrile was added. The solution was dried and dissolved again with LC mobile phase. The concentration of PGE1 in the solution was analyzed by a Liquid Chromatograph (LC)/Mass Spectrometer (MS)/MS (API3200, Applied Biosystems/MDS SCIEX, Carlsbad, CA, USA).
Murine Hindlimb Ischemia Model
Hindlimb ischemia was created in 6-week old male C57BL/6 mice as previously reported. 7, 8 Briefly, the mice were anesthetized with intraperitoneal sodium pentobarbital (60 mg/kg) injection. The proximal right femoral artery and the distal portion of the saphenous artery were ligated. All branches between these 2 sites were ligated or cauterized and the entire femoral artery was excised.
Dose-Response Study of Single Administration of PGE1-Loaded-PLGA Microspheres
Two days after femoral artery ligation, the mice were randomly divided into groups (n=20 for each) and drugs were injected in the ischemic thigh muscles as follows: no treatment (Group N); PLGA (Group PLGA); PGE1-10 μg/kgloaded PLGA (Group P10); PGE1-30 μg/kg-loaded PLGA (Group P30); and PGE1-100 μg/kg-loaded PLGA (Group P100). In all groups except N, PLGA or PGE1-loaded PLGA was dissolved in 100 μl PBS containing 0.2% tween 80 and then injected directly into the ischemic thigh muscles.
Single Local Administration of PGE1-Loaded-PLGA Microspheres vs Repeated Systemic Administration of PGE1 Solution
Two days after femoral artery ligation, the mice were randomly divided as follows (n=20 for each): no treatment (Group N); single local intramuscular injection of 100 μg/kg of PGE1 solution (Group L); daily subcutaneous injection of 7.14 μg/kg of PGE1 for 14 days (total dose 100 μg/kg, Group S); and single local intramuscular injection of PGE1-100 μg/kg-loaded PLGA (Group P100). In Group L, 100 μg/kg of PGE1 (alprostadil alfadex, Ono Pharmaceutical Co Ltd, Osaka, Japan) was dissolved in 100 μl PBS and injected directly into the ischemic thigh muscles. In Group P100, PGE1-100 μg/kg-loaded PLGA was dissolved in 100 μl PBS containing 0.2% tween 80 and then injected directly into the ischemic thigh muscles. In Group S, 7.14 μg/kg of PGE1 was dissolved in 150 μl PBS and then injected subcutaneously in the dorsum.
Hindlimb Blood Perfusion
Hindlimb blood perfusion was scanned using a laser Doppler perfusion image (LDPI) analyzer (Moor Instruments, Devon, UK) on the first day of the treatment (ie, 2 days after femoral artery ligation) and at 4 weeks after treatment. The stored images were subjected to computerassisted quantification and the average blood flow in the ischemic and non-ischemic limbs was calculated to minimize influential variables, including ambient light and temperature, perfusion was expressed as the ratio of the blood perfusion in the ischemic limb to that in the non-ischemic limb of the same mouse; that is, the LDPI index (LDPII). 7, 8 
Immunohistological Analysis
At 4 weeks after the initiation of treatment, the mice were euthanazed and perfusion-fixed with 4% paraformaldehyde. The ischemic gastrocnemius muscles were embedded in optimal cutting temperature compound (Sakura Finetechnical, Tokyo, Japan) and frozen in liquid nitrogen. Cryostat sections (5-μm thick) of the tissues were stained with rabbit polyclonal antihuman von Willebrand factor antibody (vWF; Dako Japan, Kyoto, Japan) or mouse monoclonal anti-human smooth muscle actin antibody (SMA; Sigma-Aldrich Japan K.K., Tokyo, Japan). Rabbit normal immunoglobulin fraction (Dako Japan) was used as the negative control to show antibody specificity. For each mouse, 15 different sections were photographed with a digital camera (Olympus, Tokyo, Japan). The number of vWF-positive vessels and SMA-positive vessels were counted manually in a blind fashion. 7, 8 
Statistical Analysis
The results are expressed as the mean ± standard deviation. Differences among groups were determined by 1-way Circulation Journal Vol.73, July 2009 analysis of variance followed by multiple comparisons using the Tukey test. All statistical analyses were performed using Dr SPSS II software (SPSS Inc, Chicago, IL, USA). P<0.05 was considered to be significant.
Results

Particle Size and Release Profile of PGE1-Loaded-PLGA Microspheres
The particle sizes of most PGE1-loaded-PLGA microspheres were between 15 and 40 μm (Figure 1) .
In the in vitro release study of PGE1, the percentage of remaining PGE1 in PLGA was 71.8±5.9% at 1 week, 64.5±6.2% at 2 weeks and 30.6±1.3% at 4 weeks. PGE1 was gradually released from PLGA for more than 4 weeks (Figure 1) .
In the in vivo release study of PGE1, 2 weeks after intramuscular injection of PGE1-loaded PLGA, the remaining PGE1 in the injection site at 2 weeks after injection was 64.7±16.6% and 27.7±4.6% at 4 weeks after injection, which showed that PGE1 was gradually released from PLGA for more than 4 weeks in vivo as well.
Dose-Response Study of Single Administration of PGE1-Loaded-PLGA Microspheres
The LDPII at 4 weeks in Group P100 was significantly higher than that in Group N and Group PLGA (Group P100 88±11% vs Group N 73±11% (P<0.01), Group PLGA 74± 15% (P<0.05), Group P10 76±10%, Group P30 81±13%; Figure 2 ).
Both the vascular density and αSMA-positive vessel density in Group P100 were significantly higher than in Groups N, PLGA and P10 (vascular density (vessels/m 2 ): Group P100 241±39 vs Group N 169±49 (P<0.01), Group Figure 3 ). The vehicle (Group PLGA) had no effect on the LDPII, vascular density or αSMA-positive vessel density.
Single Local Administration of PGE1-Loaded-PLGA Microspheres vs Repeated Systemic Administration of PGE1 Solution
The LDPII at 4 weeks in Group P100 was significantly higher than that in Group N, Group L and Group S (Group P100 88±11% vs Group N 73±11% (P<0.01), Group L 77±9% (P<0.05), Group S 79±11% (P<0.05); Figure 4 ). 
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The LDPII in Group S was not significantly higher than that in Group N. The vascular density in Group P100 was significantly higher than that in Group N, Group L and Group S (Group P100 241±39 vessels/m 2 vs Group N 169±49 (P<0.01), Group L 169±54 (P<0.01), Group S 201±42 (P<0.05); Figure 5 ). The vascular density in Group S was not significantly different from that in Group N.
The αSMA-positive vessel density in Group P100 was significantly higher than that in Group N, Group L and Group S (Group P100 34±10 vessels/m 2 vs Group N 18±6 (P<0.01), Group L 21±11 (P<0.01), Group S 22±10 (P<0.01); Figure 5 ). The αSMA-positive vessel density in Group S was not significantly different from that in Group N.
Discussion
Key Findings
This study showed that (1) PGE1 was gradually released from PLGA for more than 4 weeks in vitro and in vivo and (2) local administration of a single does of SR PGE1 improved blood perfusion and induced angiogenesis and arteriogenesis in murine hindlimb ischemia more efficiently than repeated systemic administration of PGE1 solution.
SR System of PGE1
PGE1 is used as treatment for PAD because it has a systemic and pulmonary vasodilating effect and also inhibits platelet aggregation. PGE1 is usually repeatedly administered intravenously for several weeks, but approximately 70% is metabolized by the lung during the first pass immediately after injection. 9 In addition, the serum concentrations of PGE1 and its biologically active metabolites rapidly decrease after intravenous injection. 10 Therefore, it is assumed that intermittent intravenous administration of PGE1 raises the concentration of PGE1 and its metabolites only for a short period of time. The efficacy of local SR of PGE1 utilizing PLGA as the carrier was evaluated in the current study in order to improve the efficiency of PGE1 therapy. PLGA has excellent biocompatibility and biodegradability and has been approved by the Food and Drug Administration for human clinical use. 6 The present study showed that PGE1 is gradually released from PLGA for more than 4 weeks. Local SR of PGE1 is assumed to maintain the tissue concentration of PGE1 in ischemic tissue at a certain level for a long time without inactivation by the lung, which may induce effective neovascularization. Local SR of several growth factors is effective for myocardial ischemia and limb ischemia without systemic side-effects. 7, 8, [11] [12] [13] [14] [15] In addition, SR of PGE1 potentiated the angiogenesis induced by SR of basic fibroblast growth factor. 12 These treatment strategies improve efficacy without systemic side-effects.
PGE1 and Angiogenesis
PGE1 has pro-angiogenic properties, 1, 16 although others have reported anti-angiogenic properties. 17 Mehrabi et al reported that PGE1 pretreatment increased CD34+ cells, vWF+ cells and VEGF-positive capillaries in explanted hearts for transplantation. [3] [4] [5] The present study showed that local administration of PGE1-loaded PLGA microspheres increased vascular density and αSMA-positive vessel density in ischemic hindlimbs, which indicated that a local SR system of PGE1 induced the formation of not only capillaries but also mature vessels. Therefore, local administration of SR PGE1 has both angiogenic and arteriogenic properties. The angiogenic effect of PGE1 has been reported to be mediated by upregulation of eNOS, 16 VEGF 4, 16, 18 and HGF. 1 PGE1 has been also reported to increase the number of endothelial progenitor cells in the blood and bone marrow in a NO-dependent manner. 19 In contrast, administration of SR PGE1 did not increase the concentrations of VEGF and HGF in the ischemic muscles in this study (data not shown). Therefore, the mechanism of neovascularization is unknown in this system. Some vasodilators induce angiogenesis. 20, 21 PGE1 has a vasodilating effect and vasodilation increases fluid shear stress, which has been reported to induce arteriogenesis 22, 23 and might be the mechanism of neovascularization by PGE1. Potassium channels also play an important role in PGE1-induced vasorelaxation, 24 and they have been reported as have a relationship to angiogenesis. 25, 26 In addition to its angiogenetic and vasodilating properties, PGE1 reportedly decreased the levels of vascular adhesion molecule-1 and intracellular adhesion molecule-1, 2,27 and reduced type-1 plasminogen activator inhibitor and Ddimer. 27, 28 Those properties may attenuate the progression of atherosclerosis and make PGE1 is a suitable drug for PAD.
Clinical Study of PGE1
In a clinical study of limb ischemia, intravenous administration of PGE1 increased the blood flow as assessed by a laser Doppler imager, 1 and increased transcutaneous oxygen pressure values. 29 However, in randomized trials for limb ischemia, the long-term efficacy of PGE1 is controversial. The ICAI study group reported a randomized controlled trial for chronic critical leg ischemia (CLI). Daily intravenous infusion of 60 μg of alprostadil for up to 28 days was effective with respect to the resolution of CLI for 6 months. 30 Brass et al and Nehler et al reported other randomized, multicenter, double-blind and controlled studies that showed that the intravenous administration of 60 μg of lipo-ecraprost, a PGE1 analog, 5 days per week for 8 weeks had no benefit in the reduction of major amputation or death at 180 days for patients with CLI. 31, 32 Further studies are therefore needed to elucidate the efficacy of PGE1 for critical limb ischemia.
Clinical Implications
This study showed that local administration of a single dose of SR PGE1 improved neovascularization more efficiently than repeated systemic administration of PGE1 solution. Therefore, local injection of SR PGE1 could be a treatment option for patients with CLI. This system does not require daily injections for several weeks and can be repeated if the effect is diminished several months later.
Study Limitation
The current study only evaluated the effect of PGE1 at 4 weeks and did not evaluate any longer term effects. Because the duration of this SR system of PGE1 is more than 4 weeks, the angiogenic properties after 4 weeks may thus decrease, so a long-term study is needed.
Conclusions
Local administration of SR PGE1 was found to enhance neovascularization in mouse hindlimb ischemia more efficiently than repeated systemic administration of PGE1.
